Biological parameters predictive of percent dense red blood cell decrease under hydroxyurea

Orphanet Journal of Rare Diseases

Volumn 10, Issue 1, 2015, Pages

  Rakotoson, Marie Georgine ^a   Di Liberto, Gaetana ^a,b   Audureau, Etienne ^c   Habibi, Anoosha ^c   Fauroux, Christine ^c   Khorgami, Sanam ^a,b   Hulin, Anne ^c   Loric, Sylvain ^c   Noizat Pirenne, France ^a,b   Galacteros, Frédéric ^a,c   Bartolucci, Pablo ^a,c  

^a UNIVERSITÉ PARIS EST CRÉTEIL   (France)

^b ETABLISSEMENT FRANÇAIS DU SANG   (France)

^c HENRI MONDOR HOSPITAL   (France)

Author keywords

Dense red blood cells; Hydroxyurea; Sickle cell disease

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; HEMOGLOBIN; HEMOGLOBIN F; HYDROXYUREA; LACTATE DEHYDROGENASE; LACTATE DEHYDROGENASE ISOENZYME;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; CELL DENSITY; CELLULAR PARAMETERS; CLINICAL TRIAL; CYTOLOGY; DRUG EFFICACY; ERYTHROCYTE; FEMALE; HEMOLYSIS; HUMAN; HUMAN CELL; LACTATE DEHYDROGENASE BLOOD LEVEL; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MEAN CORPUSCULAR HEMOGLOBIN; MEAN CORPUSCULAR VOLUME; PREDICTIVE VALUE; RETICULOCYTE COUNT; SICKLE CELL ANEMIA; SINGLE DRUG DOSE; THROMBOCYTE COUNT; TREATMENT DURATION; ANEMIA, SICKLE CELL; DRUG EFFECTS; ERYTHROCYTE DISORDER;

ADULT; ANEMIA, SICKLE CELL; ERYTHROCYTES, ABNORMAL; FEMALE; FETAL HEMOGLOBIN; HUMANS; HYDROXYUREA; MALE;

EID: 84929303433     PISSN: None     EISSN: 17501172     Source Type: Journal    
DOI: 10.1186/s13023-015-0272-3     Document Type: Article

References (22)

1. Horiuchi K, Stephens MJ, Adachi K, Asakura T, Schwartz E, Ohene-Frempong K. Image analysis studies of the degree of irreversible deformation of sickle cells in relation to cell density and Hb F level. Br J Haematol. 1993;85:356-64.
2. Bridges KR, Barabino GD, Brugnara C, Cho MR, Christoph GW, Dover G, et al. A multiparameter analysis of sickle erythrocytes in patients undergoing hydroxyurea therapy. Blood. 1996;88:4701-10.
3. Kaul DK, Fabry ME, Windisch P, Baez S, Nagel RL. Erythrocytes in sickle cell anemia are heterogeneous in their rheological and hemodynamic characteristics. J Clin Invest. 1983;72:22-31.
4. Charache S, Dover GJ, Moyer MA, Moore JW. Hydroxyurea-induced augmentation of fetal hemoglobin production in patients with sickle cell anemia. Blood. 1987;69:109-16.
5. Rodgers GP, Dover GJ, Noguchi CT, Schechter AN, Nienhuis AW. Hematologic responses of patients with sickle cell disease to treatment with hydroxyurea. N Engl J Med. 1990;322:1037-45.
6. Schwartz RS, Musto S, Fabry ME, Nagel RL. Two distinct pathways mediate the formation of intermediate density cells and hyperdense cells from normal density sickle red blood cells. Blood. 1998;92:4844-55.
7. Zen Q, Batchvarova M, Twyman CA, Eyler CE, Qiu H, De Castro LM, et al. B-CAM/LU expression and the role of B-CAM/LU activation in binding of low- and high-density red cells to laminin in sickle cell disease. Am J Hematol. 2004;75:63-72.
8. Eaton WA, Hofrichter J. Sickle cell hemoglobin polymerization. Adv Prot Chem. 1990;40:63-279.
9. Bartolucci P, Brugnara C, Teixeira-Pinto A, Pissard S, Moradkhani K, Jouault H, et al. Erythrocyte density in sickle cell syndromes is associated with specific clinical manifestations and hemolysis. Blood. 2012;120:3136-41.
10. Bartolucci P, Chaar V, Picot J, Bachir D, Habibi A, Fauroux C, et al. Decreased sickle red blood cell adhesion to laminin by hydroxyurea is associated with inhibition of Lu/BCAM protein phosphorylation. Blood. 2010;116:2152-59.
11. Danon D, Marikovsky V. Determination of density distribution of red cell population. J Lab Clin Med. 1964;64:668-73.
12. Goldberg MA, Brugnara C, Dover GJ, Schapira L, Charache S, Bunn HF. Treatment of sickle cell anemia with hydroxyurea and erythropoietin. N Engl J Med. 1990;323:366-72.
13. Charache S, Dover GJ, Moore RD, Eckert S, Ballas SK, Koshy M, et al. Hydroxyurea: effects on hemoglobin F production in patients with sickle cell anemia. Blood. 1992;79:2555-65.
14. Olnes M, Chi A, Haney C, May R, Minniti C, Taylor 6th J, et al. Improvement in hemolysis and pulmonary arterial systolic pressure in adult patients with sickle cell disease during treatment with hydroxyurea. Am J Hematol. 2009;84:530-32.
15. Paule I, Sassi H, Habibi A, Pham KP, Bachir D, Galactéros F, et al. Population pharmacokinetics and pharmacodynamics of hydroxyurea in sickle cell anemia patients, a basis for optimizing the dosing regimen. Orphanet J Rare Dis. 2011;.:. doi: 10.1186/1750-1172-6-30.
16. Adragna NC, Fonseca P, Lauf PK. Hydroxyurea affects cell morphology, cation transport, and red blood cell adhesion in cultured vascular endothelial cells. Blood. 1994;83:553-60.
17. Lew VL, Bookchin R. Osmotic effects of protein polymerization: analysis of volume changes in sickle cell anemia red cells following deoxy-hemoglobin S polymerization. J Membr Biol. 1991;122:55-67.
18. Ballas SK, Dover GJ, Charache S. Effect of hydroxyurea on the rheological properties of sickle erythrocytes in vivo. Am J Hematol. 1989;32:104-11.
19. Steinberg MH, Lu ZH, Barton FB, Terrin ML, Charache S, Dover GJ. Fetal hemoglobin in sickle cell anemia: determinants of response to hydroxyurea. Blood. 1997;89:1078-88.
20. Mehari A, Gladwin MT, Tian X, Machado RF, Kato GJ. Mortality in adults with sickle cell disease and pulmonary hypertension. JAMA. 2012;307:1254-6.
21. Thornburg CD, Dixon N, Burgett S, Mortier NA, Schultz WH, Zimmerman SA, et al. A pilot study of hydroxyurea to prevent chronic organ damage in young children with sickle cell anemia. Pediatr Blood Cancer. 2009;52:609-15.
22. Voskaridou E, Chritoulas D, Bilalis A, Plata E, Varvagiannis K, Stamatopoulos G, et al. The effect of prolonged administration of hydroxyurea on morbidity and mortality in adult patients with sickle cell syndromes: results of a 17-year, single-center trial (LaSHS). Blood. 2010;115:2354-63.